OpenDNA has entered into a major new research collaboration with Psifas, Israel’s National Initiative for Personalized Medicine, aimed at advancing how we identify and manage the risk of common diseases using artificial intelligence and genomic data.
The partnership brings together OpenDNA’s AI-powered genomic analysis platform with Psifas’s extensive clinical and genetic biobank – one of the most comprehensive in Israel. Together, the teams will develop 32 polygenic risk score (PRS) models, focusing on conditions with high prevalence and major health burden, including cardiovascular disease, breast cancer, prostate cancer, and colorectal cancer.
“All analysis will be performed in a secure, cloud-based research environment, in full compliance with ethical and privacy standards,” ensuring responsible use of data while unlocking new opportunities for disease prevention.
The collaboration has an important added benefit: results generated by OpenDNA’s models will be returned to the Psifas biobank, creating a feedback loop that enhances the database for future research and delivers long-term value to study participants.
As Prof. Gabriel Barbash, Director of Psifas, explains:
“Today, we treat diseases only after they’ve already caused harm – and that’s far too late. One of Psifas’s goals is to detect diseases during the silent incubation stage, when there’s still a chance to stop them. This collaboration is an important step in that direction, combining Israeli high-quality clinical data with smart algorithms that help us predict who needs attention early.”
Eran Feldhay, CEO of OpenDNA, adds:
“This collaboration marks a significant milestone. The data provided by Psifas will empower our AI engine to deliver real-world, clinically-relevant disease preventing genomic insights that could ultimately save lives.”
This initiative reinforces OpenDNA’s commitment to advancing proactive, data-driven healthcare through strategic collaborations with national programs and research institutions.
